People who take popular drugs for weight loss, such as Ozempic or Wegovy, may be at an increased risk of severe stomach problems, research published Thursday in the Journal of the American Medical Association finds
The mechanism is distinct from and complementary to GHRH receptor signaling, which operates through the cAMP pathway [1]
Todays article - and the first single-stock deep dive for High Risk, High Returns: Biotech Newsletter, unpacks Amylyx, a US-based biotech focusing on rare diseases, with a market capitalization of $731 million and having seen substantial volatility in recent years after declining from $2.4bn valuation in 2022, but rebounded recently close to +445% afte
Today, theyre a fully loaded magazine of silver bullets aimed at obesity, addiction, cancer, sleep apnea, and a growing list of other diseases and chronic conditions
Chapter 5, Human Vitamin and Mineral Requirements: report of a joint FAO/WHO expert consultation, Bankok, Thailand
